LEO LUZNIK to CD8-Positive T-Lymphocytes
This is a "connection" page, showing publications LEO LUZNIK has written about CD8-Positive T-Lymphocytes.
Connection Strength
1.288
-
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024 09 12; 144(11):1168-1182.
Score: 0.772
-
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022 11 01; 132(21).
Score: 0.170
-
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018 11 02; 3(21).
Score: 0.129
-
Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 04; 24(4):666-677.
Score: 0.121
-
Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide. Blood Adv. 2022 09 13; 6(17):4994-5008.
Score: 0.042
-
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629.
Score: 0.039
-
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May; 14(5):499-509.
Score: 0.016